Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875033 | 0.78 | PBRM1 (0.43) | ALDH1A1LMNAPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL874411 | 0.70 | KDM4E (0.48) | ALDH1A1LMNAMAPTPOLBKMT2A | |
| SCHEMBL15192693 | 0.69 | MAP3K5 (0.39) | MAP3K5ALDH1A1KMT2A | |
| SCHEMBL892359 | 0.66 | BACE1 (0.31) | MAPT | |
| SCHEMBL891784 | 0.64 | BACE1 (0.38) | MAP3K5 | |
| SCHEMBL15192882 | 0.64 | MAP3K5 (0.40) | MAP3K5ALDH1A1SMN1; SMN2 | |
| SCHEMBL31288930 | 0.64 | — | — | |
| SCHEMBL16136560 | 0.63 | MAOB (0.47) | MAP3K5ALDH1A1SMN1; SMN2 | |
| SCHEMBL31426114 | 0.62 | PKM (0.39) | MAP3K5MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL9931654 | 0.62 | PBRM1 (0.38) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | MAP3K5 2515/4885ALDH1A1 2346/4885LMNA 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.